CN1217675C - 治疗更年期综合症的药物及其制造方法 - Google Patents
治疗更年期综合症的药物及其制造方法 Download PDFInfo
- Publication number
- CN1217675C CN1217675C CN01107471XA CN01107471A CN1217675C CN 1217675 C CN1217675 C CN 1217675C CN 01107471X A CN01107471X A CN 01107471XA CN 01107471 A CN01107471 A CN 01107471A CN 1217675 C CN1217675 C CN 1217675C
- Authority
- CN
- China
- Prior art keywords
- group
- medicine
- female
- rat
- climacteric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 206010027304 Menopausal symptoms Diseases 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title description 18
- 238000002360 preparation method Methods 0.000 title description 2
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 20
- 210000003101 oviduct Anatomy 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 6
- 239000003549 soybean oil Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 5
- 239000000084 colloidal system Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 238000000194 supercritical-fluid extraction Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 25
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 239000000796 flavoring agent Substances 0.000 abstract description 3
- 235000019634 flavors Nutrition 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 239000005556 hormone Substances 0.000 abstract 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 210000000750 endocrine system Anatomy 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000007721 medicinal effect Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 46
- 241000700159 Rattus Species 0.000 description 44
- 241001465754 Metazoa Species 0.000 description 20
- 230000037396 body weight Effects 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 210000004291 uterus Anatomy 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 12
- 210000001672 ovary Anatomy 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 210000001541 thymus gland Anatomy 0.000 description 9
- 231100001252 long-term toxicity Toxicity 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000003054 hormonal effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 208000031975 Yang Deficiency Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 230000037118 bone strength Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- KDPFMRXIVDLQKX-ISGXEFFDSA-N (+)-Curdione Natural products CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)/CC1=O KDPFMRXIVDLQKX-ISGXEFFDSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- QRMPRVXWPCLVNI-UHFFFAOYSA-N Curcumenol Natural products C1C(=C)C2CCC(C)C22CC(C(C)C)C1(O)O2 QRMPRVXWPCLVNI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- KDPFMRXIVDLQKX-NHFJXKHHSA-N Germacr-1(10)-ene-5,8-dione Chemical compound CC(C)[C@@H]1CC(=O)[C@@H](C)CC\C=C(C)\CC1=O KDPFMRXIVDLQKX-NHFJXKHHSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010024419 Libido decreased Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- ISFMXVMWEWLJGJ-NZBPQXDJSA-N curcumenol Chemical compound CC1=C[C@](O2)(O)C(=C(C)C)C[C@@]22[C@@H](C)CC[C@H]21 ISFMXVMWEWLJGJ-NZBPQXDJSA-N 0.000 description 2
- KDPFMRXIVDLQKX-UHFFFAOYSA-N curdione Natural products CC(C)C1CC(=O)C(C)CCC=C(C)CC1=O KDPFMRXIVDLQKX-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000881 depressing effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000007905 drug manufacturing Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 239000000745 gonadal hormone Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000037315 hyperhidrosis Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010066364 Hypersexuality Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001336827 Rana chensinensis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 208000024776 abnormal vaginal bleeding Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 208000002938 adenomyoma Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000036773 apocrine secretion Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 231100000877 autonomic nervous system dysfunction Toxicity 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229940010073 hydrocortisone injection Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008542 thermal sensitivity Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量(g/kg) | E2(pg/ml) | FSH(mlo/ml) | LH(mlo/ml) |
正常模型坤泰口服液更年康 | 3.22.41.21.5 | 4.52±0.352.12±0.73Δ3.01 ±0.45**2.94±0.34**2.65±0.31*2.36±0.51 | 2.40±0.303.44±0.21Δ2.90±0.25**2.93±0.60*3.01±0.692.94±0.61* | 3.07±0.895.04±1.05Δ3.95±0.57**3.99±0.41**4.05±0.21**3.81±0.51** |
组别 | 剂量(g/kg) | 子宫重(mg) | 子宫重量系数 |
正常模型坤泰口服液更年康 | 3.22.41.21.5 | 142.3±27.650.4±18.2Δ123.3±12.7**115.9±9.6**75.6±24.1*65.1±10.4* | 6.30±1.302.08±1.14Δ5.80±0.62**5.13±0.51**3.56±1.25*2.98±0.67* |
组别 | 剂量(g/kg) | E2(pg/ml) | FSH(g/cm3) | 骨强度(kg/cm) |
正常模型坤泰口服液骨肾胶囊 | 3.21.20.5 | 0.221±0.0350.121±0.027Δ0.199±0.033**0.164±0.056*0.183±0.088* | 2.425±0.0572.063±0.054Δ2.267±0.049**2.204±0.160*2.220±0.182* | 4.69±0.822.43±0.71Δ4.01±0.69**3.58±1.20*3.61±1.43* |
组别 | 剂量(g/kg) | 体重增长率 | 死亡时间(-20℃) | 胸腺(mg/10g) | 脾脏(mg/10g) |
正常模型坤泰口服液骨肾胶囊 | 3.22.40.5 | 31.9±17.46.3±6.9Δ18.9±5.9**15.4±7.1**11.3±7.8* | 69.2±21.238.8±15.4Δ68.7±24.2**61.3±13.2**64.3±19.8** | 26.4±10.912.3±7.8Δ19.5±6.8*18.2±4.2*12.3±4.5 | 70.1±15.641.6±7.5Δ51.2±12.0*48.3±5.7*42.3±11.9 |
组别 | 剂量(g/kg) | 全血粘度(mpas) | 血液粘度(mpas) | HCT(%) | ||
1 | 50 | 200s-1 | ||||
正常模型阿斯匹林坤泰 | 0.13.22.4 | 9.33±1.0512.78±2.30ΔΔ9.57±0.81**10.88±0.46*9.89±0.70** | 4.28±0.355.77±1.09ΔΔ4.34±0.38**4.77±0.25*4.67±0.25** | 3.75±0.334.98±0.90ΔΔ3.78±0.35**4.25±0.31*4.10±0.21** | 1.56±0.181.79±0.25Δ1.46±0.30*1.60±0.131.64±0.11 | 39.1±2.043.0±4.4Δ39.0±2.6*38.9±4.0*39.5±3.69 |
组别 | 剂量(g/kg) | 游泳时间(min) | P |
正常坤泰口服液 | 33.22.4 | 21.6±9.846.6±11.249.6±13.343.2±8.6 | <0.01<0.01<0.05 |
时间(天) | 对照组 | 小剂量组 | 大剂量组 |
07142128354249566370 | 190.0±11.6209.0±22.0224.0±23.0236.5±28.5254.3±42.9259.5±43.3266.0±46.2271.5±49.4278.0±52.9287.5±57.3295.3±61.7 | 192.3±14.8206.8±26.2218.3±29.3229.0±31.8246.0±36.6255.0±38.9262.0±39.2268.0±42.5274.0±44.1279.0±45.0284.0±48.7 | 189.0±12.2206.0±21.5216.3±23.3227.3±26.0241.3±31.5250.5±37.4256.5±39.3267.6±40.2274.3±43.1284.0±47.3296.8±52.6 |
时间 | 对照组 | 小剂量组 | 大剂量组 | |
RBC(T/L)Hb(g/L)HCTMCV(fL)MCH(Pg)MCHC(g/L) | D56D70D56D70D56D70D56D70D56D70D56D70 | 7.36±0.738.00±0.77134.3±10.6144.4±8.80.69±0.0590.74±0.03594.7±8.893.4±7.118.3±1.918.2±1.6192.5±2.1194.3±4.0 | 7.40±0.707.00±1.32130.0±11.2129.3±21.90.70±0.0610.67±0.09092.8±4.896.1±8.718.1±1.018.6±1.5194.6±2.1192.8±10.1 | 7.60±0.767.28±0.95137.1±11.8134.3±10.90.67±0.0590.69±0.05890.9±5.696.8±10.017.6±1.218.6±1.5193.5±3.2193.4±3.8 |
时间 | 对照组 | 小剂量组 | 大剂量组 | |
WBC(G/L)GRAN(G/L)LYM(G/L) | D56D70D56D70D56D70 | 6.89±2.667.04±1.922.25±1.581.93±0.853.94±2.204.42±1.04 | 7.99±3.086.77±2.452.89±1.122.14±0.814.33±2.074.09±1.92 | 6.79±1.777.42±2.281.96±0.532.43±0.774.42±1.654.26±1.62 |
时间 | 对照组 | 小剂量组 | 大剂量组 | |
PLT(G/L)凝血时间(min) | D56D70D56D70 | 904.9±270.1968.7±124.22.10±0.441.77±0.72 | 1043.7±233.3976.8±278.92.63±0.441.95±0.68 | 1048.7±160.6966.5±95.92.04±0.682.04±0.69 |
时间 | 对照组 | 小剂量组 | 大剂量组 | |
ALT(u)AST(u)ALP(lu/L)BUN(mmol/L)Cr(μmol/L)TP(g/L)Alb(g/L)Glu(mmol/L)Tch(mmol/L)VLDL(mmol/L)TG(mmol/L) | D56D70D56D70D56D70D56D70D56D70D56D70D56D70D56D70D56D70D56D70D56D70 | 50.5±13.759.1±13.9220.6±43.0198.3±45.9144.8±33.4110.4±49.08.1±0.910.2±1.572.1±5.773.7±7.770.8±4.777.2±6.234.8±4.033.4±2.04.18±1.265.46±0.591.12±0.171.39±0.260.27±0.130.33±0.090.60±0.300.74±02.0 | 53.4±21.249.6±20.4175.3±52.5164.9±35.0*148.0±70.894.7±46.67.4±1.58.6±1.169.5±7.765.3±8.3*69.0±7.470.9±5.631.6±3.432.8±3.34.57±1.046.76±1.13*1.03±0.211.41±0.330.28±0.110.33±0.110.62±0.210.74±0.24 | 59.2±14.6*50.9±19.0190.5±60.0181.4±38.9131.0±70.6121.6±51.27.5±1.38.6±1.369.1±10.267.4±7.068.7±4.372.6±2.933.5±3.029.9±2.74.44±0.665.34±1.991.06±0.220.90±0.22*0.29±0.090.32±0.200.63±0.170.67±0.49 |
检测指标 | 时间 | 对照组 | 小剂量组 | 大剂量组 |
心肝脾肺肾肾上腺(mg)甲状腺(mg)脑前列腺睾丸子宫及卵巢 | D56D70D56D70D56D70D56D70D56D70D56D70D56D70D56D70D56D70D56D70D56D70 | 0.28±0.0280.30±0.0412.58±0.342.39±0.200.40±0.120.42±0.200.63±0.130.62±0.150.58±0.0480.58±0.05317.13±6.5916.48±6.144.89±1.194.87±1.020.56±0.0760.55±0.130.18±0.0930.24±0.140.77±0.140.78±0.0730.22±0.0580.27±0.017 | 0.27±0.0260.30±0.0702.77±0.282.59±0.580.46±0.130.35±0.0660.71±0.150.65±0.150.62±0.0670.58±0.1118.84±5.9317.41±4.644.50±1.433.87±0.710.60±0.0910.54±0.0930.22±0.0620.34±0.0780.81±0.140.89±0.190.26±0.100.27±0.12 | 0.31±0.0420.28±0.0162.78±0.502.27±0.190.39±0.150.36±0.0430.66±0.180.51±0.110.64±0.0850.58±0.03717.78±4.1813.75±3.464.21±1.765.30±1.560.60±0.0930.48±0.0970.13±0.0590.24±0.0830.93±0.100.74±0.150.29±0.082*0.29±0.12 |
♀ | ♂ |
d0 d718 2420 2518 2518 2719 2520 2720 2619 2720 2818 23 | d0 d719 2621 2718 2420 2818 2719 2519 2620 2820 2321 29 |
19.1±1.1 25.9±1.3 | 19.5±1.1 26.2±1.7 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN01107471XA CN1217675C (zh) | 2001-01-18 | 2001-01-18 | 治疗更年期综合症的药物及其制造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN01107471XA CN1217675C (zh) | 2001-01-18 | 2001-01-18 | 治疗更年期综合症的药物及其制造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1319417A CN1319417A (zh) | 2001-10-31 |
CN1217675C true CN1217675C (zh) | 2005-09-07 |
Family
ID=4656398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN01107471XA Expired - Fee Related CN1217675C (zh) | 2001-01-18 | 2001-01-18 | 治疗更年期综合症的药物及其制造方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1217675C (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1806840B (zh) * | 2005-01-21 | 2010-06-16 | 中国科学院上海药物研究所 | 一种中药复方制剂及其制备方法 |
CN103690672B (zh) * | 2013-12-31 | 2016-08-31 | 贵阳新天药业股份有限公司 | 用于治疗妇女卵巢功能异常引起的功血的控释制剂及其制备方法 |
CN105688088A (zh) * | 2016-04-03 | 2016-06-22 | 马兆峰 | 一种用于治疗更年期抑郁症综合征的药物制剂 |
CN106344553B (zh) * | 2016-08-03 | 2019-12-13 | 江西省妇幼保健院 | 莪术醇在制备用于通过干预子宫内膜间质细胞而达到治疗子宫腺肌病的药物中的用途 |
CN111991405B (zh) * | 2020-08-28 | 2021-10-29 | 广州中医药大学第一附属医院 | 莪术二酮联合白果新酸在制备促进骨形成药物中的应用 |
-
2001
- 2001-01-18 CN CN01107471XA patent/CN1217675C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1319417A (zh) | 2001-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1157196C (zh) | 用于防治肝癌的草药制剂 | |
US20040109904A1 (en) | Antineoplastic drug | |
CN103635199A (zh) | 治疗癌症的草药组合物 | |
CN1314422C (zh) | 一种补益气血、温阳健脾十味扶正的药物及其制备方法 | |
CN1305513C (zh) | 一种广谱治疗癌症的中药制剂及其制备方法 | |
CN1217675C (zh) | 治疗更年期综合症的药物及其制造方法 | |
CN1478508A (zh) | 一种治疗脂肪肝的中药组合物及其制备方法 | |
CN1839884A (zh) | 鲜鹿茸冻干粉的制备及其含鲜鹿茸冻干粉的中药制剂和用途 | |
CN1060657C (zh) | 防治肿瘤放、化疗毒副反应的固真药剂及其制备方法 | |
CN1895337A (zh) | 党参黄芪组合物提高晚期肿瘤患者生存质量的制药用途 | |
CN109692309A (zh) | 治疗非酒精性脂肪肝祛湿活血方 | |
CN102526444A (zh) | 一种补肾壮阳的中药组合物及其制备方法 | |
CN102091312B (zh) | 生姜与花椒组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
CN1966001A (zh) | 一种治疗炎症的药物及其制备方法 | |
CN1965888A (zh) | 一种治疗乳腺癌的中药组合物 | |
CN1537564A (zh) | 一种广谱治疗癌症的中药制剂 | |
CN105727089A (zh) | 含艾叶的药物组合物用于制备治疗肠易激综合症药物中的用途 | |
CN112022896A (zh) | 一种抗肿瘤中药复方软胶囊制剂及其制备方法和应用 | |
CN100556448C (zh) | 一种抑制和治疗肿瘤的中药药物组合物及其制备方法和应用 | |
CN1246016C (zh) | 一种治疗更年期综合征的中药复方制剂及制备方法 | |
CN101053624A (zh) | 一种治疗前列腺增生、慢性前列腺炎的中药及其制备工艺 | |
CN1471954A (zh) | 一种中药戒毒药物 | |
CN102370953A (zh) | 一种治疗癌性及术后疼痛的纯中草药制剂及其制备方法 | |
CN1100550C (zh) | 一种适用于各种癌症的中药组合物 | |
CN1931256A (zh) | 一种用于戒毒的中药胶囊制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: NANFANG MEDICAL UNIV. Free format text: FORMER OWNER: DENG JIANGZHU Effective date: 20041112 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20041112 Address after: 510515, Guangzhou, Guangzhou province and harmony Applicant after: Southern Medical University Address before: 510515 Department of traditional Chinese medicine, Guangdong and Guangzhou First Military Medical University Applicant before: Deng Hongzhu |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: DONGFANG YAOLINYAOYEYOUXIANGONGSI ADDRESS Free format text: FORMER OWNER: NANFANG MEDICAL UNIV. ADDRESS Effective date: 20081121 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20081121 Address after: Southern Medical University, 1023 Sha Ha Road, Guangdong, Guangzhou Patentee after: Orient Pharmaceutical Co., Ltd. Address before: Tonghe, Guangzhou, Guangdong Province Patentee before: Southern Medical University |
|
ASS | Succession or assignment of patent right |
Owner name: DONGFANG YAOLINYAOYEYOUXIANGONGSI Free format text: FORMER OWNER: NANFANG MEDICAL UNIV. Effective date: 20081121 |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050907 Termination date: 20130118 |
|
CF01 | Termination of patent right due to non-payment of annual fee |